Gossamer Bio Inc.   Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (2015)

Organization Overview

First Clinical Trial
2017
NCT03473236
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. | GB002, Inc. | GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | GB004, Inc. | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Gossamer Bio Inc.